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Angiogenesis, the formation of blood vessels, is a major
factor in£uencing tumor growth and metastatic capa-
city, and VEGF is the prototype angiogenic factor.
VEGF expression is also found in the dermis and tumor
stroma during the course of melanoma progression.
Various oncogenes such as c-Src, v-Raf, and Ras, and
multiple environmental stimuli, including hypoxia and
ultraviolet radiation (UVR), can regulateVEGF expres-
sion under certain conditions.
We have constructed several cell lines from a radial
growth phase, primary human melanoma cell line,
WM35.We have stably transfected WM35 cells with mu-
tant activated H-ras, N-ras, dominant negative p53, or
empty vector. In this report, we determined how VEGF
expression and release from these melanoma cell lines
were a¡ected by the following important factors asso-
ciated with melanoma initiation and progression: hy-
poxia, UVR, activated Ras, dominant negative p53,
and culture conditions mimicking radial growth phase
melanoma (monolayer culture) and vertical growth
phase melanoma (spheroid culture). We found that hy-
poxia, but not UVR, up-regulates VEGF mRNA ex-
pression and protein release in these melanoma cells. In
addition, activated Ras and dominant negative p53 en-
hances the hypoxia-induced VEGF protein release. We
propose that hypoxia-induced VEGF release promotes
tumor progression, especially in melanomas with Ras
or p53 mutations. Key word: angiogenesis/VEGF. J Invest
Dermatol 121:910 ^917, 2003
A
ngiogenesis, the formation of blood vessels, is a ma-
jor factor in determining tumor growth and meta-
static capacity (Fidler and Ellis, 1994; Folkman, 1995;
Hanahan and Folkman, 1996). Tumor growth re-
quires fresh nutrients (growth factors) and oxygen
supplied via neovascularization. The most widely studied me-
chanism known to induce angiogenesis is the release of endothe-
lial cell growth factors. Vascular endothelial growth factor
(VEGF), also known as vascular permeability factor, is a potent
angiogenic and endothelial cell-speci¢c mitogen (Leung et al,
1989; Senger et al, 1993). VEGF is expressed and secreted at low
levels by most normal cells but is constitutively expressed at
much higher levels by many human tumors and tumor cell lines,
including breast, colon, ovarian, bladder, and brain tumors and
melanomas (Leung et al, 1989; Shweiki et al, 1992; Senger et al,
1993; Dvorak et al, 1995; Ferrara, 1995; Kolch et al, 1995; White
et al, 1995).
There is a growing body of literature that supports the role of
angiogenesis in the development and spread of a variety of solid
tumors. Several ¢ndings suggest that VEGF is an important an-
giogenic factor in melanoma angiogenesis (Cla¡ey et al, 1996; Er-
hard et al, 1997; Marcoval et al, 1997; Salven et al, 1997; Graeven
et al, 2001). Cla¡ey et al (1996) found that by stimulating angio-
genesis, VEGF promotes melanoma growth. Erhard et al (1997)
found that a gradual rise in the mean vascular density correlates
with melanoma progression and that the transition from hori-
zontal- to vertical-growth-phase melanoma is accompanied by
induction of VEGF protein expression and accumulation of
VEGF in the stroma. In addition, it appears that VEGF is upre-
gulated during the course of melanoma progression and dissemi-
nation and that tumor-in¢ltrating cells expressing VEGF may
contribute to the progression of melanoma (Salven et al, 1997).
Recently, Graeven et al (2001) concluded that despite their ¢nding
that VEGF does not play an essential role in the tumorigenic
phenotype of human melanoma cells,VEGF does promote mela-
noma progression since overexpression of VEGF accelerates mel-
anoma tumor expansion in vivo.
Certain oncogenes have also been shown to upregulate VEGF
expression, including c-Src (Mukhopadhyay et al, 1995), v-Raf
(Grugel et al, 1995), and Ras (Grugel et al, 1995; Rak et al, 1995a,
b). Ras mutations have been shown to be an important progres-
sion factor in melanoma (Ball et al, 1994; Fujita et al, 1999), but
there are currently no data on the e¡ects of Ras onVEGF release
in melanoma. Mutations in the p53 tumor suppressor gene can
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cause a slight upregulation of VEGF, which can be further en-
hanced by agents that activate protein kinase C (Kieser et al,
1994). Wild-type p53 also inhibits hypoxia-inducible factor-1
(HIF-1)-stimulated transcription (Blagosklonny et al, 1998). HIF-
1, in turn, stimulates transcription of a number of genes including
VEGF, although higher levels of p53 are required to inhibit HIF-
1 than are necessary to transcriptionally activate p53 target genes.
Numerous studies devoted to understanding the regulation of
VEGF expression have found that many environmental stimuli
can upregulate VEGF. In particular, hypoxia is a major inducer
of VEGF expression in virtually all cell types examined (Shweiki
et al, 1992; Mukhopadhyay et al, 1995). Some cytokines and
growth factors are also capable of inducing VEGF, including in-
terleukin-1b and -6, insulin-like growth factor-1, epidermal
growth factor, and transforming growth factor-a (Brogi et al,
1994; Li et al, 1995; Cohen et al, 1996; Goad et al, 1996). In addition,
ultraviolet radiation (UVR) has been shown to upregulateVEGF
expression in keratinocyte-derived cell lines and cultured human
¢broblasts (Brauchle et al, 1996; Mildner et al, 1999; Trompezinski
et al, 2000, 2001).
Melanoma is the most aggressive skin cancer and the prognosis
for patients diagnosed with melanoma is often poor. The only
known de¢ned environmental risk factor for this tumor is ultra-
violet exposure. No previous studies have addressed the e¡ects of
UVR onVEGF expression in melanomas.
It has also been shown in other cell types that oncogenes
and hypoxia can synergistically induceVEGF expression (Mazure
et al, 1996; White et al, 1997). Previously, no studies have been
carried out to address how these oncogenes, along with envi-
ronmental stimuli such as hypoxia and UVR, a¡ect VEGF
expression and release in melanoma.
The use of both monolayer and single-cell suspension culture
systems for studying cancer in vitro has been well documented.
Cancer cells grown in spheroid culture mimic the growth char-
acteristics of solid tumors by providing a three-dimensional
environment with multiple and varied cell-cell and/or cell-extra-
cellular matrix interactions. Previous studies have suggested that
the signals that regulate growth in monolayers di¡er from those
in spheroids (LaRue et al, 1998).
In this report, we determined the e¡ects of several impor-
tant factors associated with melanoma initiation and progression
on VEGF expression and release from human melanoma cell
lines, including hypoxia, UVR, activated Ras, dominant-nega-
tive p53 (DNp53), and culture conditions mimicking radial-
growth-phase melanoma (monolayer) and vertical-growth-phase
melanoma (spheroid).
MATERIALS AND METHODS
Cell lines and culture conditions WM35 is a low-malignancy,
primary human melanoma cell line. Cell lines designated as H-ras, N-ras,
and Neo were previously constructed by stably transfecting H-ras, N-ras,
or empty vector, respectively, into WM35 cells (Fujita et al, 1999). We
performed Ras activity assays and found that the H-ras and N-ras cell
lines had 30% more Ras activity than the control cell line, Neo (WM35
cells stably transfected with an empty vector) (data not shown). The
DNp53 cell line was similarly constructed by transfecting WM35 cells
with the pc53-SCX3 plasmid (Khlgatian et al, 2002). This plasmid
contains the neo gene and the DNp53 mutant gene with a valine to
alanine substitution at codon 143 (Baker et al, 1990). Approximately twice
as much p53 protein can be detected by western blot in the DNp53
construct than in the control cells (Khlgatian et al, 2002).
The cell lines were maintained as monolayer cultures in RPMI 1640
(Gibco BRL, Gaithersburg, MD) with 400 mg/mL G418 (Geneticin,
Gemini Bio-Products, Inc., Woodland CA) and 5% fetal bovine serum
(Gemini Bio-Products, Inc.). The epidermoid carcinoma cell line A431was
cultured in RPMI 1640 (Gibco BRL) with 5% fetal bovine serum
(Gemini Bio-Products, Inc.). The keratinocyte-derived cell line HaCaT
was cultured in DMEM (Gibco BRL) with 5% fetal bovine serum
(Gemini Bio-Products, Inc.).
In monolayer culture, 3104 to 5104 cells in 3 mL of culture medium
were seeded in each well of six-well plates for 48 h before the media
were exchanged for fresh media. Cells were incubated for an additional
24 h before the media were saved and stored for measurement of
VEGF release. Also at this time, the cells were harvested, counted with a
hemocytometer, or stored for DNA measurement.
Multicellular spheroids were generated by the liquid overlay technique
as described (Rofstad et al, 1986). Brie£y, 6- or 24 -well tissue culture plates
were coated with 0.5 or 1.5 mL, respectively, of prewarmed 1% agarose
(Sigma) solution in RPMI 1640 (Gibco BRL) with 5% FBS. After the
agarose solidi¢ed to form a thin layer with a gentle meniscus (B20 min),
a suspension of cells in the same complete medium without agarose was
overlayed. The cells were incubated undisturbed at 371C, 5% CO2. Forty-
eight hours later, cells with medium were harvested and centrifuged; the
supernatants were saved for quanti¢cation of VEGF release and the cells
were counted with a hemocytometer or stored for DNA measurement.
Quanti¢cation of VEGF release The media used for growing cells
were harvested as described above, and VEGF release was measured by
a ELISA kit following manufacturer’s instruction (R & D Systems,
Minneapolis, MN). The amount of VEGF release was normalized by total
DNA content, cell number, or optical density resulting from MTS assay
(cell proliferation assay) (Promega, Madison,WI) from each sample.
DNA quantitation Cells were collected into Eppendorf tubes and
pelleted at 325 g for 3 min. The cell pellets were dissolved in 0.5 M
NaOH (0.25 mL) and were frozen before quanti¢cation. Lysates were
neutralized and the DNA concentrations were quanti¢ed using a Hoechst
33258 £uorescent assay as previously described (Labarca and Paigen, 1980;
Hedlund and Miller, 1994).
CellTiter 96 Aqueous One solution cell proliferation assay for
quantitation of cell viability (MTS assay) The reagents were
obtained from Promega, and procedures were followed according to the
manufacturer’s instruction. Brie£y, the assay is a colorimetric method
for determining the number of viable cells. The reagent contains a
tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfopheny)-2H-tetrazolium, inner salt) and an electron-
coupling reagent (phenazine ethosulfate). Assays were performed by adding
20 mL of the reagent to each 96-well plate containing 100 mL of cells with
medium. The viability of control condition was set as 100%, and other
conditions were compared to this to obtain a percentage of viability.
UVR treatment Melanoma cells were plated at 0.5105 per well as
monolayer cultures in triplicate wells of tissue culture treated six-well
plates in 3 mL of culture media per well. Forty-eight hours later, cells
were then treated with the indicated amount of UVR. Medium was
removed from tissue culture plates or dishes in which cells were grown
and replaced with phosphate-bu¡ered saline (PBS; without phenol red). A
solar simulator (Dr Honle blue-light 2001, 220 V, 50 Hz, 400 W) was
equipped with the manufacturer’s ¢lter h2, allowing light from 295 to
400 nm to pass. The solar simulator was warmed up for 10 to 15 min
before exposing cells. Radiometric measurement was performed using an
IL1350 radiometer/photometer (International Light, Inc., Newburyport,
MA) and the manufacturer’s UVB sensor calibrated at 290 nm or the
manufacturer’s UVA sensor calibrated at 360 nm. Samples were irradiated
with varying doses of UVB (mJ/cm2) or sham-irradiated, with the tops of
dishes removed at a distance of 8 to 12 in. from light source. PBS was
aspirated and fresh growth medium added to the dish for remainder of
experiment. Cells were harvested for mRNA measurement at 4 h after
UVR exposure. Twenty-four hours after UVR exposure, cell culture
supernatants were removed and stored for quantitation of VEGF release
and cells were harvested and counted with a hemacytometer or stored for
DNA measurement.We also set up the parallel experiments for MTS assays
to assess the viability of cells following UVR.
HaCaT cells were used as a positive control because it has been reported
that low-dose UVR inducesVEGF production in these cells (Brauchle et al,
1996; Mildner et al, 1999; Trompezinski et al, 2001).We used the exact same
protocol described by Mildner et al for HaCaT cells (Brauchle et al, 1996;
Mildner et al, 1999; Trompezinski et al, 2001), which excluded serum from
the culture medium.
We have performed the control experiment and found that there was no
di¡erence between PBS and mediumwithout phenol red during the UVR
treatments (data not shown). We also performed UVR experiments and
found that the presence (or absence) of serum had no e¡ect on our
¢nding that UVR does not stimulate VEGF release from these melanoma
cells (data not shown).
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Hypoxia treatment Cells were grown in monolayer culture for 2 d, and
media were changed immediately before the cells were exposed to either
normoxic (control) or hypoxic (o0.5% O2) conditions for indicated
times. The hypoxic environment was achieved by displacing the air in
the incubator with condensed N2 gas, and the N2 gas was controlled
by a compact gas oxygen controller (Model PROOX110, Reming
Bioinstruments Company, Red¢eld, NY). Cells were harvested for
preparation of total RNA at 6 h after hypoxia treatment. In parallel experi-
ments, cell culture supernatants were saved and stored for quanti¢cation
of VEGF release, and cells were harvested and counted with a hemo-
cytometer or stored for DNA measurement at indicated times of post-
hypoxia treatment.
mRNA quanti¢cation Total RNA was isolated using Trizol reagent
(Gibco BRL) according to the manufacturer’s instruction. cDNA was
generated from 1 mg of total RNA using the random primer protocol of
the Superscript II preampli¢cation system for ¢rst stand cDNA synthesis
(Gibco BRL). Real-time quantitative PCR was performed using SYBR
green technology with the Perkin-Elmer GeneAmp 5700 sequence
detection system according to the manufacturer’s instructions. Primers for
VEGF (50 -TAC CTC CAC CATGCCAGG TG-30 and 50 -GATGAT TCT
GCC CTC CTC CTT-30) were synthesized by the Microchemical Facility
of the Emory University School of Medicine and optimized according to
the SYBR green protocol. Standard curves were generated from serial
dilutions of a cDNA and the data normalized for di¡erences in GAPDH.
Ras activation assays Ras activation assays were performed using a
manufacturer’s reagents and instructions (Upstate Biotechnology, Lake
Placid, NY). Brie£y, cells were harvested and lyzed using manufacturer’s
lysis bu¡er. Raf-1 RBD agarose-conjugated beads were used to precipitate
activated Ras proteins. Proteins were detached from beads and analyzed by
western blot analysis.
Statistical analyses The e¡ects of hypoxia, UVR, activated Ras,
DNp53, and culture conditions on the melanoma cells tested were com-
pared to the respective controls by using the Microsoft Excel Student’s
t test (two-tailed and assuming unequal variances). Signi¢cance was esta-
blished at the level of po0.05.
RESULTS
VEGF release from melanoma cells is much less than that
from A431 cells Our lab has constructed stable transfectants
of the low-malignancy WM35 human primary melanoma cell
line overexpressing activated H-ras, N-ras, and DNp53 proteins
(Fujita et al, 1999, #132; Khlgatian et al, 2002, #178). To deter-
mine relative amounts of Ras activity in WM35 transfectants,
we performed Ras activity assays and found that the H-ras and
N-ras cell lines had 30% more Ras activity than the control cell
line, Neo (WM35 cells stably transfected with an empty vector)
(data not shown). Approximately twice as much p53 protein can
be detected by western blot in cells transfected with the DNp53
construct than in the control cells (Khlgatian et al, 2002). Here,
we used these stable transfectants to investigate the e¡ects of
activated H-ras, N-ras, and DNp53 on VEGF release in WM35
cells. All results were normalized to the control cell line, Neo,
for comparison (Fig 1). All the melanoma cell lines tested
secreted VEGF into the culture medium. Nevertheless, the epi-
dermoid carcinoma cell line, A431, secreted 20-fold more VEGF
than these melanoma cells (Fig 1).
In a more extensive study of VEGF secretion from melanoma
cells grown under di¡erent culture conditions, we found that
there was a small increase of VEGF release in H-ras cells (45%
more, t test of H-ras vs Neo, p¼ 0.00004) and a decrease of
VEGF release in DNp53 cells (25% less, t test of DNp53 vs
Neo, p¼ 0.0006) compared to the control in monolayer culture
(Fig 2). A similar trend was found in spheroid culture H-ras
cells secreted more and DNp53 secreted less VEGF than Neo
cells (Fig 2). A Student’s t test showed statistically signi¢cant
di¡erences between H-ras and Neo (p¼ 0.004) and between
DNp53 and Neo (p¼ 0.0007). In addition, grown in spheroid
culture, only Neo cells produced statistically signi¢cantly more
VEGF than grown in monolayer culture (Fig 2, 0% more and
p¼ 0.017). Nevertheless, the di¡erences in VEGF secretion
among these cell lines and between the two growth conditions
were very small compared to the VEGF release from A431.
Mildner et al (1999) showed that A431 produces a similar amount
of VEGF to that of cultured primary keratinocytes. From both
our results and their study, we can infer that the melanoma cells
we tested produce very little VEGF compared to primary
keratinocytes. Early-stage melanomas are surrounded by keratino-
cytes in vivo, suggesting that activated mutant Ras or DNp53
has an insigni¢cant e¡ect on total VEGF present in early-stage
melanoma tumors. Spheroid culture condition also has no signi¢-
cant e¡ects onVEGF release in these cells.
Hypoxia induces mRNA expression and VEGF release To
examine whether hypoxia a¡ected VEGF mRNA expression
and protein secretion into the culture media in these melanoma
cells, we grew the cells in monolayer culture under either
normoxic (control) or hypoxic (o0.5% O2) conditions. RNA
samples were harvested for measuring VEGF mRNA levels after
6 h of hypoxia treatment (Fig 3A) and in the parallel
Figure1. Melanoma cells produce less VEGF compared to A431.
Cell lines designated as H-ras, N-ras, dominant-negative p53 (DNp53),
and Neo were previously constructed by stably transfecting H-ras, N-ras,
DNp53, or empty vector, respectively, into a primary human melanoma
cell line, WM35. These melanoma cells or an epidermoid cell line A431
were grown in monolayer cultures for 2 d before the media were replaced
with fresh media. Cells were harvested for preparation of total RNA 6 h
later, and samples were used for quanti¢cation of VEGF mRNA expres-
sion by real-time quantitative RT-PCR (A). TheVEGF mRNA expression
was normalized by GAPDH mRNA expression in each sample. In parallel
experiments, cell culture supernatants were saved and stored 24 h later for
quanti¢cation of VEGF release by ELISA (B). The VEGF release was nor-
malized by total amount of DNA from each sample. The VEGF release
from the control cell line Neo was set equal to 1, and the relative VEGF
release from other cells was calculated as the fold of VEGF release com-
pared to Neo cells. Data represent means7SEM.
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experiments media were harvested for measuring VEGF release
following 24, 36, and 48 h of hypoxia treatment (Fig 3B and
data not shown). Similar results for VEGF release were obtained
from 36 and 48 h of hypoxia treatment (data not shown). These
data demonstrate that hypoxia is a very potent inducer of VEGF
mRNA expression and protein secretion for these melanoma
cells.
We also performed a Student’s t test to analyze whether the
induction of VEGF expression by hypoxia in these cells was
signi¢cantly higher compared to the induction of VEGF
expression by hypoxia in the control cell line, Neo. Only the
statistically signi¢cant p values were labeled in Fig 3. The
induction of VEGF mRNA in these cell lines was comparable
except for N-ras clone S1. Nevertheless, induction of VEGF
protein release by hypoxia was signi¢cantly higher than the
control in two di¡erent clones of H-ras, clone S1 of N-ras cells,
and DNp53 cells (Fig 3B). These results suggest that both
activated Ras mutations and DNp53 may enhance hypoxia
induction of VEGF release from these cells, possibly at a post-
translational level.
UVR does not induce VEGF expression or VEGF release
from these melanoma cells We examined whether UVR
a¡ected VEGF mRNA expression and protein secretion in these
melanoma cells. DNp53 cells were used as a control for p53
dependence of UV experiment. VEGF mRNA expression was
quantitated by real-time RT-PCR (Fig 4A). In both monolayer
and spheroid culture, 100 mJ per cm2 UVB did not increase
VEGF mRNA levels, but reduced VEGF mRNA levels in all
melanoma cells we tested (Fig 4A). Similar results on VEGF
release were observed at these relatively high doses of UVR
treatment (Fig 4B,C). We found that both 50 and 100 mJ per
cm2 UVB signi¢cantly reduced VEGF release in all melanoma
cell lines tested. The e¡ects of UVR on VEGF expression or
release were more prominent in monolayer than in spheroid
culture (Fig 4B,C). These calculations were normalized with
GAPDH for mRNA expression and total amount of DNA for
the VEGF release.
HaCaTcells were used as a positive control, because it has been
reported that low-dose UVR induces VEGF production in these
cells (Brauchle et al, 1996; Mildner et al, 1999; Trompezinski et al,
2001).We found that both low and high doses of UVR increased
VEGF release in HaCaT cells (Fig 5 and data not shown).
Furthermore, using the same low doses of UVB, 10 and 25 mJ
per cm2, VEGF release from melanoma cells was una¡ected
(Fig 5).
We also performed MTS assays for viability of these cells, and
found that there was very little cell death (0%^5%) following
low doses of UVR (10 and 25 mJ/cm2) and moderate cell death
(10%^25%) in the highest dosage (50 and 100 mJ/cm2) (data not
shown). Under all conditions, UVR did not increase VEGF
production in these melanoma cells. The presence (or absence) of
serum had no e¡ect on our ¢nding that UVR did not stimulate
VEGF release from these melanoma cells (data not shown).
Figure 2. Spheroid culture does not a¡ect VEGF release from mel-
anoma cell lines. The following melanoma cells were used: Neo (the
control cell line), H-ras, N-ras, and DNp53. Cells were grown in mono-
layer culture or in spheroid culture for 2 d before the media were harvested
for measurement of VEGF release by ELISA.The amount of VEGF release
was normalized by total amount of DNA from each sample. The VEGF
release from the control cell line Neo in monolayer culture was set equal
to 1, and the relativeVEGF release from other conditions or other cells was
calculated as relative VEGF release compared to that from Neo cells in
monolayer culture. This is a summary of two independent experiments of
total 12 samples per data point. Data represent means7SEM.
Figure 3. Hypoxia upregulatesVEGF mRNA expression and VEGF
release in melanomas. The following melanoma cells were used: Neo,
two clones of H-ras (S2, C7), two clones of N-ras (S1, C8), and DNp53.
Cells were grown in monolayer culture for 2 d, and media were changed
immediately before the cells were exposed to either normoxic (control) or
hypoxic (o 0.5% O2) conditions for indicated times.The data were plotted
as the relative expression in VEGF mRNA (A) or VEGF release (B) upon
hypoxia compared to respective control. (A) Cells were treated with hy-
poxia for 6 h before being harvested for preparation of total RNA, and
samples were used for quanti¢cation of VEGF mRNA expression by real-
time quantitative RT-PCR.TheVEGF mRNA expression was normalized
by GAPDH mRNA expression in each sample. The data were plotted as
the relative expression in VEGF mRNA upon hypoxia compared to re-
spective control in each cell line. (B) At 24 h after hypoxia treatment, cell
culture supernatants were saved and stored for quanti¢cation of VEGF re-
lease.The VEGF release was normalized by total DNA content from each
sample. A Student’s t test analysis was performed, and the p values were
calculated as the comparisons of the induction of VEGF expression be-
tween these cells and Neo cells. Only the p values, which are statistically
signi¢cant, are labeled in the ¢gure (po0.05). This is a summary of two
independent experiments. Data represent means7SEM.
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DISCUSSION
In this study, we measured VEGF release from several melanoma
cell lines originally derived from a low-malignancy, radial-
growth-phase melanoma cell line and modi¢ed by transduction
of mutated Ras or p53.We found that the baseline levels of VEGF
released from these cells are quite low. These data are consistent
with previous reports (Erhard et al, 1997; Salven et al, 1997). Those
studies found lower levels of VEGF production in early-stage
melanomas compared to melanomas representing the transition
from radial-growth-phase to vertical-growth-phase melanoma
or metastatic melanomas (Erhard et al, 1997; Salven et al, 1997).
We found that the levels of VEGF release from these melano-
ma cells are much lower compared to an epidermoid cell line,
A431. Mildner et al (1999) showed that A431 produces a similar
amount of VEGF to that of cultured primary keratinocytes. It
follows, therefore, that the melanoma cells we tested should pro-
duce very little VEGF compared to primary keratinocytes. Sev-
eral studies have shown that keratinocytes are a major source of
VEGF production in the skin (Detmar et al, 1994; Ballaun et al,
1995;Weninger et al, 1996). Radial-growth-phase melanoma cells
may not be required to produce high levels of VEGF if the pri-
mary keratinocytes surrounding the tumor are secreting su⁄cient
quantities of this growth factor. Only when a melanoma mass
reaches a critical volume, and tumor cells from inside the tumor
mass are removed from neighboring keratinocytes, would VEGF
production be more critically important for these larger advanced
melanomas. Several ¢ndings supporting this concept showing a
correlation between VEGF production and melanoma progres-
sion (Erhard et al, 1997; Salven et al, 1997).
We investigated the regulation of VEGF production a¡ected
by environmental factors, hypoxia and UVR in these WM35
melanoma cells. Our studies show that hypoxia is a very potent
inducer for VEGF expression and secretion (up to 30-fold of
baseline) in these melanoma cells. In addition, under these hy-
poxic conditions, we found that melanoma cells secrete a similar
amount of VEGF to that of A431 (see Figs 1, 3). This is consistent
with a previous ¢nding by Cla¡ey et al (1998). In that study, it was
found that hypoxia induces VEGF expression in human M21
melanoma cells (Cla¡ey et al, 1998). In addition, our data also sug-
gest that mutant Ras or DNp53 seems to enhance the induction
of VEGF production by hypoxia at a post-transcriptional level.
Figure 4. UVR does not induceVEGF mRNA expression or VEGF
release in melanomas. The following melanoma cells were grown in
monolayer culture or spheroid culture for 2 d before being subjected to
UVR treatment. (A) Cells were treated with UVB 100 mJ per cm2 for 4 h
before being harvested for preparation of total RNA, and samples were
used for quanti¢cation of VEGF mRNA expression by real-time quantita-
tive RT-PCR. The VEGF mRNA expression was normalized by GAPDH
mRNA expression in each sample. The data were plotted as the relative
amount of VEGF mRNA upon UVR compared to respective control in
each cell line. The relative amount of VEGF mRNA in the control of each
cell line was set equal to 1. (B,C) Cells were grown in monolayer (B) or
spheroid culture (C) upon UVR treatment at indicated doses. Cell culture
supernatants were saved and stored for quanti¢cation of VEGF release at 24
h after UVR treatment. The data were plotted as the relative amount of
VEGF release upon UVR compared to respective control in each cell line.
The amount of VEGF release in the control of each cell line was set equal
to 1. The VEGF release was normalized by total DNA content from each
sample. Data represent means7SEM.This is one representative experiment
of three experiments with triplicates each.
Figure 5. Lower doses of UVR do not induce VEGF release in
melanomas. Cells were grown in monolayer culture for 2 d before being
subjected to UVR treatment. Cells were treated with indicated amount of
UVB for 24 h before quanti¢cation of VEGF release.The data were plotted
as the relative amount of VEGF release upon UVR compared to respective
control in each cell line. The amount of VEGF release in the control of
each cell line was set equal to 1. The VEGF release was normalized by
MTS assay from each sample. Data represent mean7SEM.
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The uncontrolled proliferation of cells in an organ will always
lead to low oxygen tension because the di¡usion range of oxygen
will eventually be exceeded. The response to hypoxia is di¡eren-
tially regulated at the level of speci¢c cell types or layers in var-
ious organs, and it is possible that there is preferential tumor
development in areas of increased hypoxia responsiveness. Trans-
fection of cells with a mutant form of p53 has been shown to
result in the potentiation of the PMA-dependent activation of
VEGF mRNA expression (Kieser et al, 1994). Oncogenes have
also been shown to potentiate hypoxia-inducedVEGF expression
in other cell types (Mazure et al, 1996;White et al, 1997). Our re-
sults suggest that oncogenes such as mutant Ras and DNp53
might provide these melanoma cells some survival advantage by
increasing hypoxia responsiveness, thus resulting in increased an-
giogenesis as a consequence of increased production of angio-
genic agents such as VEGF.
Hypoxia-induced VEGF expression is regulated by multiple
mechanisms including transcriptional activation, mRNA stabili-
zation, and alternative initiation (see reviews Berra et al, 2000;
Paulding and Czyzyk-Krzeska 2000; Semenza 2000a, b). Cla¡ey
et al (1998) found that hypoxia-induced VEGF expression is
mediated by increased transcription and mRNA stability in hu-
man M21melanoma cells.
Transcriptional activation of the VEGF gene in response to
hypoxia is mediated by HIF-1 (see review, Semenza 2000a, b).
HIF-1 is a heterodimeric transcription factor composed of a con-
stitutively expressed HIF-1b subunit and an O2- and growth
factor-inducible HIF-1a subunit (Semenza 2000a, b). HIF-1a
subunit expression is controlled by O2-regulated ubiquitination
and proteasomal degradation (Salceda and Caro, 1997; Huang
et al, 1998; Kallio et al, 1999; Sutter et al, 2000).
Increased VEGF mRNA stability induced by hypoxia is
mediated, at least in part, by speci¢c interactions between a de-
¢ned mRNA stability sequence in the 30 -untranslated region and
distinct hypoxia-induced mRNA-binding proteins (Levy et al,
1996a, b, 1997; Cla¡ey et al, 1998).
Loss of function of p53 has been found to increase HIF-1a ex-
pression by decreasing its ubiquitination (Ravi et al, 2000). Acti-
vated H-ras has been shown to increase VEGF expression via the
PI3 kinase or MAP kinase pathway, depending upon the cell type
(Rak et al, 1995; Arbiser et al, 1997; Mazure et al, 1997; Rak et al,
2000). The MAP kinase cascade can control VEGF expression by
several mechanisms (see review Berra et al, 2000): (1) p42/p44
MAPKs activate the VEGF promoter at the proximal (^88/^66)
region where Sp1/AP-2 transcriptional factor complexes are re-
cruited; (2) p42/p44 MAPKs can directly phosphorylate HIF-1a
and enhance HIF-1 transcriptional activation activity; and (3)
MAPKs activated under various cellular stresses (p38MAPK and
JNK) can stabilize the VEGF mRNA.
Our data suggest that the enhancement of hypoxia-induced
VEGF expression by activated H-ras or DNp53 is not mediated
by increasing VEGF mRNA levels. It is possible that activated
N-ras or DNp53 might regulate other controls of VEGF expres-
sion such as alternative translational initiation. Our studies do not
de¢ne why activated H-ras and N-ras appear to regulate VEGF
expression di¡erently. It is possible that activated H-ras and N-
ras have di¡erent substrate speci¢cities, and they can activate the
downstream targets at di¡erent e⁄ciencies. Nevertheless, further
studies are needed to investigate these possibilities.
Studies have shown that with UVR exposure human keratino-
cyte-derived cell lines and human dermal ¢broblasts upregulate
VEGF expression and production (Brauchle et al, 1996; Mildner
et al, 1999; Trompezinski et al, 2001). Nevertheless, there are con-
£icting results regarding the e¡ect of UVRonVEGF production
in primary keratinocytes. Longuet et al reported that UVB upre-
gulates VEGF in primary keratinocytes. In contrast, Mildner et al
(1999) found that UVB does not induce VEGF production in
primary keratinocytes, and high doses of UVA actually reduces
VEGF production signi¢cantly. There are methodologic di¡er-
ences between these two studies. Mildner’s group used a solar
simulator as we did in our studies; however, Longuet et al used
light sources with narrow bandwidth without speci¢c informa-
tion on the equipment. Therefore, Mildner’s model may be a clo-
ser model to the in vivo situation and be more relevant to the
photobiology of human skin.
Our studies showed that a high dose of UVB reduces VEGF
expression or production in the melanoma cells tested and that
lower doses of UVB have little e¡ect. These data indicate that
UVR does not promote melanoma progression through VEGF
release. Nevertheless, UVR has been found to increase other fac-
tors, such as IL-8 expression in primary melanomas, resulting in
increased tumor growth and metastasis (Singh et al, 1995; Wood
and Richmond, 1995; Luca et al, 1997; Begum et al, 1999). In addi-
tion, UVR stimulates expression of many factors in keratinocytes
including b-FGF, NGF, endothelin-1, IL-8, etc., and these factors
might promote melanoma progression indirectly (Schwarz and
Luger, 1989; Imokawa et al, 1992; Gilchrest et al, 1996; Bielenberg
et al, 1998).
In our study, spheroid culture conditions did not a¡ect VEGF
mRNA expression or protein release signi¢cantly. In addition,
the e¡ects of UVR onVEGF expression or release were less ob-
vious in spheroid than in monolayer culture. Nevertheless, we
cannot rule out the possibility that the reason for the diminished
e¡ect in spheroid culture is that UVR cannot penetrate spheroid
culture as well as cells grown as monolayers.
There is evidence that in di¡erent cell types VEGF expression
can be regulated di¡erently in response to the same stimuli (Claf-
fey et al, 1996). Understanding the diverse mechanisms by which
cells overexpress VEGF, and which mechanisms are operating in
speci¢c tumor types, may help in the design of e¡ective antican-
cer therapies. A recent publication also suggests that loss of TSP-1
might be a key event in the switch from an antiangiogenic to an
angiogenic phenotype and might be even more critical for mela-
noma formation thanVEGF secretion (Graeven et al, 2001). It will
be important to investigate whether these oncogenes and/or en-
vironmental stimuli control TSP-1 expression in melanoma.
In summary, we found that hypoxia upregulated VEGF
mRNA expression and protein release in the melanoma cells de-
rived fromWM35. UVR did not increase VEGF release in these
melanoma cells grown in either spheroid or monolayer culture.
In addition, activated Ras enhances the hypoxia-induced VEGF
protein release inWM35 cells.We proposed that hypoxia-induced
VEGF release promotes tumor progression, especially in melano-
mas with activated Ras mutations.
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